Agents to Avoid-Require Special Precautions With/QT Agents (mono deleted 09/16/2013)
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of your medicines may affect your heart's rhythm.
What might happen:
Taking two or more medicines that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know right away that you are taking these medications together. Let your doctor know right away if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
2.Zmax (azithromycin) US prescribing information. Pifzer Inc January, 2013.
3.Fanapt (iloperidone) US prescribing information. Novartis Pharmaceuticals Inc January, 2013.
4.Serentil (mesoridazine besylate) US prescribing information. Novartis Pharmaceuticals Corporation August, 2000.
5.Avelox (moxifloxacin hydrochloride) US prescribing information. Bayer Pharmaceuticals Corporation August, 2012.
6.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation December, 2012.
7.Invega (paliperidone) US prescribing information. Janssen Pharmaceuticals, Inc. April, 2011.
8.Qualaquin (quinine sulfate) US prescribing information. AR Scientific, Inc. April, 2013.
9.Xenazine (tetrabenazine) US prescribing information. Ovation Pharmaceuticals, Inc. September, 2008.
10.Thioridazine tablet, US prescribing information. Mylan Pharmaceuticals September, 2010.
11.Trisenox (arsenic trioxide) US prescribing information. Cell Therapeutics, Inc. March, 2001.
12.Sirturo (bedaquiline) US prescribing information. Janssen Therapeutics December, 2012.
13.USFood and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm March 28, 2012.
14.Xalkori (crizotinib) US prescribing information. Pfizer Inc. January, 2012.
15.Halaven (eribulin mesylate) US prescribing information. Eisai, Inc. November, 2010.
16.Potiga (ezogabine) US Prescribing Information. Valeant Pharmaceuticals March, 2012.
17.Gilenya (fingolimod) US prescribing information. Novartis Pharmaceuticals Corporation May, 2012.
18.MHRA United Kingdom. Fingolimod (Gilenya): transient bradycardias and heart block after first dose - strengthened cardiovascular monitoring. Drug Safety Update Feb 2012;5(7):A1.
19.Ablavar (gadofosveset trisodium) US prescribing information. Lantheus Medical Imaging, Inc. December, 2010.
20.Kon P. Dear UK Healthcare Professional: Direct Healthcare Professional Communication on ondansetron (Zofran and generics) and dose-dependent QT interval prolongation - new dose restriction for intravenous (IV) use. GlaxoSmithKline UK Ltd August 5, 2012.
21.Zofran (ondansetron) US prescribing information. GlaxoSmithKline November, 2012.
22.USFood and Drug Administration. FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron). available at: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm September 15, 2011.
23.Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) US prescribing information. Avanir Pharmaceuticals August, 2011.
24.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
25.Fareston (toremifene citrate) US prescribing information. GTx, Inc. March, 2011.
26.Fareston (toremifene citrate) UK summary of product characteristics. Orion Pharma (UK) Limited January, 2009.
27.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP July, 2013.
28.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
29.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.